ARWR · Arrowhead Pharmaceuticals Inc
United States · RS rating 33 · As of 2026-11-03
| Price | 59.53 USD |
|---|---|
| 1-day change | -0.1% |
| RS rating (overall / 1M / 3M / 12M) | 33 / 45 / 19 / 81 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 33 / 17 / 32 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -522.7% |
| Sales growth Q/Q | +3.0% |
| Distance from 52-week high | +33.5% |
| Market cap (USD) | $10.4B |